Status:

COMPLETED

Low Dose Morphine to Relieve Dyspnea in Acute Respiratory Failure (OPIDYS)

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Acute Respiratory Failure

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This study evaluates a pharmacological intervention to relieve dyspnea in intensive care unit patients. Indeed, opioids can be particularly beneficial since 1) dyspnea and pain share many similarities...

Detailed Description

Randomized, double-blind, placebo-controlled, parallel-group, single-center phase 2 pilot study.The experimental group will receive an intravenous titration of morphine followed by a subcutaneous admi...

Eligibility Criteria

Inclusion

  • Adult patients ≤ 75 years
  • Admitted in intensive care for an acute respiratory failure defined as a respiratory rate\> 24 / min or signs of respiratory distress such as labored breathing or paradoxical inspiration, or SpO2 \<90% in ambient air
  • Spontaneous ventilation, either under standard oxygen, high flow oxygen or non invasive ventilation
  • Dyspnea ≥ 40 on an dyspnea-VAS from zero (no dyspnea) to 100 (worst possible dyspnea)
  • Richmond agitation and sedation scale (RASS) between 0 and 2.
  • No confusion, as defined by the CAM-ICU
  • Signed informed consent

Exclusion

  • Intubated patient
  • Intubation planned upon admission
  • Hearing or visual impairment
  • Insufficient command of French
  • Previous psychiatric or cognitive disorders known
  • Moribund patient
  • Known hypersensitivity to opioids
  • Severe renal insufficiency (creatinine clearance \<30 ml / min)
  • Severe hepatocellular insufficiency (factor V \<50%)
  • Any formal contra-indication of opiates
  • Opioid use within the 24 hours before inclusion
  • Pregnancy or breastfeeding
  • Minor and protected adult
  • Exclusion period due to inclusion in another clinical trial
  • Previous inclusion in this study
  • No affiliation to social security

Key Trial Info

Start Date :

December 16 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 7 2022

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT04358133

Start Date

December 16 2020

End Date

October 7 2022

Last Update

October 25 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Groupe Hospitalier Pitié Salpetriere

Paris, France, 75013